153 related articles for article (PubMed ID: 37590985)
41. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria.
Travaglino A; Raffone A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Histopathology; 2019 Apr; 74(5):676-687. PubMed ID: 30347477
[TBL] [Abstract][Full Text] [Related]
42. Management of endometrial precancers.
Trimble CL; Method M; Leitao M; Lu K; Ioffe O; Hampton M; Higgins R; Zaino R; Mutter GL;
Obstet Gynecol; 2012 Nov; 120(5):1160-75. PubMed ID: 23090535
[TBL] [Abstract][Full Text] [Related]
43. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
[TBL] [Abstract][Full Text] [Related]
44. Conservatively treated endometrial intraepithelial neoplasia/cancer: Risk of intrauterine synechiae.
Cordeiro Mitchell CN; Hunkler KF; Maher JY; Garbose RA; Gornet ME; Whiting-Collins LJ; Christianson MS
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101930. PubMed ID: 33022448
[TBL] [Abstract][Full Text] [Related]
45. Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
İşçi Bostancı E; Durmuş Y; Duru Çöteli AS; Kayıkçıoğlu F; Boran N
Turk J Med Sci; 2021 Aug; 51(4):2066-2072. PubMed ID: 34013707
[TBL] [Abstract][Full Text] [Related]
46. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Acosta-Torres S; Murdock T; Matsuno R; Beavis AL; Stone RL; Wethington SL; Levinson K; Grumbine F; Ferriss JS; Tanner EJ; Fader AN
Gynecol Oncol; 2020 May; 157(2):348-356. PubMed ID: 32085863
[TBL] [Abstract][Full Text] [Related]
47. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X; Niu J; Shi C; Liu Z
Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
[TBL] [Abstract][Full Text] [Related]
48. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
Raffone A; Catena U; Travaglino A; Masciullo V; Spadola S; Della Corte L; Piermattei A; Insabato L; Zannoni GF; Scambia G; Zullo F; Bifulco G; Fanfani F; Di Spiezio Sardo A
Gynecol Oncol; 2021 Jun; 161(3):795-801. PubMed ID: 33812697
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium.
Cirpan T; Terek MC; Mgoyi L; Zekioglu O; Iscan O; Ozsaran A
Eur J Gynaecol Oncol; 2006; 27(4):389-92. PubMed ID: 17009632
[TBL] [Abstract][Full Text] [Related]
50. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
[TBL] [Abstract][Full Text] [Related]
51. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
52. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
[TBL] [Abstract][Full Text] [Related]
53. YTHDF2 is a novel diagnostic marker of endometrial adenocarcinoma and endometrial atypical hyperplasia/ intraepithelial neoplasia.
Bian PP; Liu SY; Luo QP; Xiong ZT
Pathol Res Pract; 2022 Jun; 234():153919. PubMed ID: 35512522
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
Tamauchi S; Kajiyama H; Utsumi F; Suzuki S; Niimi K; Sakata J; Mizuno M; Shibata K; Kikkawa F
J Obstet Gynaecol Res; 2018 Jan; 44(1):151-156. PubMed ID: 29121428
[TBL] [Abstract][Full Text] [Related]
55. Pax2 expression in simultaneously diagnosed WHO and EIN classification systems.
Joiner AK; Quick CM; Jeffus SK
Int J Gynecol Pathol; 2015 Jan; 34(1):40-6. PubMed ID: 25473752
[TBL] [Abstract][Full Text] [Related]
56. Endometrial Hyperplasia.
Ring KL; Mills AM; Modesitt SC
Obstet Gynecol; 2022 Dec; 140(6):1061-1075. PubMed ID: 36357974
[TBL] [Abstract][Full Text] [Related]
57. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
[TBL] [Abstract][Full Text] [Related]
58. The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Guan J; Chen XJ
Front Endocrinol (Lausanne); 2022; 13():1041535. PubMed ID: 36387903
[TBL] [Abstract][Full Text] [Related]
59. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.
Mandelbaum RS; Ciccone MA; Nusbaum DJ; Khoshchehreh M; Purswani H; Morocco EB; Smith MB; Matsuzaki S; Dancz CE; Ozel B; Roman LD; Paulson RJ; Matsuo K
Am J Obstet Gynecol; 2020 Jul; 223(1):103.e1-103.e13. PubMed ID: 31978437
[TBL] [Abstract][Full Text] [Related]
60. Comparison of endometrial cancer risk in patients with endometrial precancerous lesions: WHO 1994 vs EIN classification.
Kender Erturk N; Basaran D; Salman C
J Obstet Gynaecol; 2022 May; 42(4):692-695. PubMed ID: 34415826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]